Physician profile
Michael L Arvanitis
NPI 1144243684
$2,220.30
in general payments reported to CMS, 2019-2025
10 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $135 · 2021: $733 · 2023: $514 · 2024: $348 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thd America, INC. | $797.57 | 2020-2025 | |
| Intuitive Surgical, INC. | $427.42 | 2019-2021 | |
| Ethicon US, LLC | $422.71 | 2019-2025 | Echelon Flex, Enseal |
| Davol INC. | $220.34 | 2021-2024 | Phasix Mesh |
| Teleflex LLC | $199.09 | 2023 | Weck |
| Kerecis Limited | $64.65 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Graftguide |
| Medtronic, INC. | $46.85 | 2023-2024 | Signia, Interstim, Sonicision |
| Pacira Pharmaceuticals Incorporated | $17.14 | 2024 | Exparel |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.74 | 2019 | |
| Covidien LP | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Arvanitis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.